Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Prescription pattern of anti-asthmatic drugs for adults in asthma outpatient department in a tertiary care hospital

Narendra Babu S.




Abstract

Background: Various groups of drugs are prescribed for the management of bronchial asthma. Choosing correct group is necessary for compliance and good outcome.

Aims and Objectives: The aims and objectives of the study are to know the prescribing pattern of anti-asthmatic drugs for adults.

Materials and Methods: 500 asthma patients prescription were analyzed from the MMC/RGGGH, Chennai.

Results: 654 prescriptions were screened and 500 prescriptions were taken for data analysis. The data showed 67% men and 33% women. Most of them received combination therapy (85%) than monotherapy (15%). Beta 2 agonists (salbutamol) formed major anti-asthmatic group (68%). Steroids group formed next (47%). Deriphyllin was prescribed for 108 patients (22%), cetrizine (anti-histamine) for 55 patients (11%), and montelukast (leukotriene antagonists) for 45 patients (9%). About 76% patients took oral tablet and 24% took inhalers.

Conclusion: β 2 agonists were preferred more than steroids group. Combination therapy is given more than monotherapy. Majority patients in our study were given oral route when compared to inhalational route.

Key words: Prescription Pattern; Anti-asthmatic Drug; Adults






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.